What is Halozyme Therapeutics's deferred revenue?

Halozyme Therapeutics (HALO) reported deferred revenue of $5.7M in Q1 2026.

How has Halozyme Therapeutics's deferred revenue changed year-over-year?

Halozyme Therapeutics's deferred revenue increased by 612.5% year-over-year, from $800K to $5.7M.

What is the long-term trend for Halozyme Therapeutics's deferred revenue?

Over 2 years (2020 to 2022), Halozyme Therapeutics's deferred revenue has grown at a -2.4% compound annual growth rate (CAGR), from $5.77M to $5.5M.

Halozyme Therapeutics HALO Deferred Revenue

Deferred Revenue at other companies

BridgeBio PharmaBBIO

$6.12M-65.1%

Arrowhead ResearchARWR

$108.54M+151%

AlkermesALKS

$0-100%

Ionis PharmaceuticalsIONS

$69.2M-14.7%

West Pharmaceutical ServicesWST

——

AptarGroupATR

——

Other financials

Income statement

See full

Revenue$376.7M+42.2%

Gross profit$297.5M+37.4%

Operating income$184.5M+30.4%

Net income$150.0M+27.1%

EPS (diluted)$1.22+31.2%

Balance sheet

See full

Cash & equivalents$312.0M+76.9%

Total debt$2.2B+41.7%

Total equity$219.6M-54.5%

Total assets$2.7B+21.7%

Cash flow

See full

Operating cash flow$180.1M+16.8%

CapEx$3.7M+294%

Free cash flow$176.3M+15.0%

Valuation

See full

Market cap$8.13B-2.9%

Enterprise value$10B+3.0%

P/E13.4×-3.8×

P/S5.4×-2.3×

Profitability

See full

Gross margin82.8%-0.7pp

Operating margin59.3%+9.0pp

Net margin47.9%+6.5pp

FCF margin44.3%-1.5pp

Returns & leverage

See full

Return on equity124.5%+12.7pp

Debt / equity9.9×+6.7×

Current ratio2.8×-5.6×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RevenueRemainingPerformanceObligation.

The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Halozyme Therapeutics's deferred revenue?: Halozyme Therapeutics (HALO) reported deferred revenue of $5.7M in Q1 2026.
How has Halozyme Therapeutics's deferred revenue changed year-over-year?: Halozyme Therapeutics's deferred revenue increased by 612.5% year-over-year, from $800K to $5.7M.
What is the long-term trend for Halozyme Therapeutics's deferred revenue?: Over 2 years (2020 to 2022), Halozyme Therapeutics's deferred revenue has grown at a -2.4% compound annual growth rate (CAGR), from $5.77M to $5.5M.